– Our Platform
An innovative, targeted approach to treating cancer
Our treatment specifically targets unique features of cancer cells, including externalized phosphatidylserine and tumor cell lysosomes by utilizing a small lysosomal protein known as Saposin C.
– Our Pipeline
A Pipeline-in-a-Product asset with potential for multiple indications
BXQ-350 is the foundation of our pipeline. Early clinical results have shown a strong safety and tolerability profile.
– clinical trials
Update
Our clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.
Resources
Resources
News
Bexion Pharmaceuticals, Inc. to Present at the Precision Medicine World Conference (PMWC) 2020
FOR IMMEDIATE RELEASE [Covington, KY~ January 15, 2020] Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that Dr. Ray Takigiku, Founder and CEO of the Company will present an overview and recent advancements of its lead compound, BXQ-350 in the Immunotherapy Showcase of the PMWC 2020 conference, ... Read More
Cincinnati Enquirer: 8 Cincinnati biotech companies with big steps to watch in 2020
Excerpt: Cincinnati has become a nurturing place for bright ideas in biotechnology, and 2020 could bring big advancements. The Cincinnati USA Regional Chamber of Commerce estimates the industry contributes more than $3 billion to the area economy. Nearly 800 locations employ more than 13,000 workers who are making average salaries of about $100,000 a ... Read More